leadf
logo-loader
viewOpen Orphan PLC

Open Orphan primed for profitability after transformational year

In the results statement, the company said it was seeing “unprecedented growth opportunities"

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said it was targeting operational profitability by the third quarter of the year following its merger with hVIVO.

The enlarged business, which provides outsourced services for the life sciences industry, said it was also expecting to remove a further €2.5mln in costs in the second half of the year.

In an update alongside its full-year results, Open Orphan talked of “unprecedented growth opportunities as pharma focuses funding on Covid-19 and respiratory diseases”.

This, it said, had led to the development of a strong pipeline of opportunities, for challenge studies along with the wider contract research services offered by the group.

Certainly, the company has been extremely busy in the first six months of the year as hVIVO has launched a “best-in-class” coronavirus testing service and its Venn Life Sciences arm landed a major contract with a vaccine developer.

The aforementioned pipeline of opportunities, meanwhile, includes two significant human challenge studies generating significant near-term revenue, and expansion of lab services. Venn's traditional pharma consulting business “continues to perform well”, investors were told.

The results for the year ended December 31 revealed the enlarged Open Orphan would have generated revenues of €27.1mln and an operating loss of €14.2mln.

After raising almost €20mln since the start of the year, Open Orphan is funded to “complete its transition and leverage a broader service offering to an enlarged and combined customer base”.

“The merger with hVIVO, post period end, has given us a full-service business, with world-class facilities, motivated colleagues and a strong pipeline of work and transforms out business into the world leader in the testing of vaccines and anti-virals through human challenge model clinical trials,” said chairman Cathal Friel.

In the results statement, the firm said a strategic review was underway to monetise its 49% holding of Imutex and “other non-core investments” such as the 62.5% stake in PrEP Biopharm.

Quick facts: Open Orphan PLC

Price: 23 GBX

AIM:ORPH
Market: AIM
Market Cap: £153.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan signs UK government contract to development COVID-19 Human...

Open Orphan's (LON:ORPH) Chairman Cathal Friel talks to Proactive London after announcing a contract with the UK Government for the development of a COVID-19 human challenge study model. Friel explains that the company, hVIVO, is the world's leader in this sector, having safely run more human...

1 week, 1 day ago

2 min read